CHMP recommends Jaypirca to treat relapsed or refractory mantle cell lymphoma
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Jaypirca, intended for the treatment of relapsed or refractory mantle cell lymphoma (MCL)
Jaypirca will be available as 50 mg and 100 mg film-coated tablets. The active substance of Jaypirca is pirtobrutinib, a protein kinase inhibitor . Pirtobrutinib is a reversible, noncovalent inhibitor of Bruton’s tyrosine kinase, which is involved in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion.
The benefit of Jaypirca is its ability to bring about a response in patients with relapsed and refractory mantle cell lymphoma. The most common side effects are fatigue, neutropenia, diarrhoea and contusion.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.